This Government Contract opportunity from Department Of Health And Human Services was posted on January 18, 2022. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Award of Anthim (obiltoxaximab) 600mg/6ml for Injection
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Office of the Assistant Secretary for Preparedness and Response, Division of Strategic National Stockpile, awarded a sole source Firm Fixed Price contract to Elusys Therapeutics, Inc. for the manufacture and vendor managed inventory of the FDA approved Anthrax Antitoxin pharmaceutical, Anthim (obiltoxaximab) Injection. The scope of work includes rotation and cold-chain distribution services to ensure the availability and viability of the medication. The contract was initially awarded on August 6, 2021, and definitized on January 12, 2022, with a total value of 80,864,000.00 dollars. The period of performance extends from August 6, 2021, through February 25, 2023, with performance based in Parsippany, New Jersey.
General Info
Contract Value
$80,864,000Place of Performance
Parsippany, NJ, 07054, USASet-Aside
Award Issued Date
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Submission Closed
Organization & Contact Information
Full Description
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
